文献速递母胎医学产科

探索基因组测序对胎儿先天性心脏缺陷的诊断效用

Exploring the diagnostic utility of genome sequencing for fetal congenital heart defects.
PubMed 文献 · Prenat Diagn · 2022-04-27

该初步研究对13例核型和/或染色体微阵列结果无诊断的先天性心脏缺陷(CHD)胎儿 trio 进行30X基因组测序(GS),4/13(30.8%)获得诊断,检出DNAH5、COL4A1、PTPN11、KRAS致病或可能致病变异;GS未明确遗传病因的9例中8例有随访,其中5例(60%)父母选择继续妊娠。

要点

  • 对核型/染色体微阵列无诊断的CHD胎儿 trio,GS在4/13(30.8%)中提供诊断。
  • 检出DNAH5、COL4A1、PTPN11、KRAS致病或可能致病变异。
  • GS未明确遗传病因的9例中8例有随访,5例(60%)父母选择继续妊娠。

核心结论

  • GS较常规检测扩展了变异类型的诊断范围,揭示了胎儿心脏异常的遗传病因。
  • GS未提示已知遗传异常的患者似乎更倾向于选择继续妊娠,尤其当心脏缺陷可手术修复时。
  • 作者提供证据支持将GS应用于CHD胎儿。

研究设计与样本

  • 初步研究,对13例核型和/或染色体微阵列结果无诊断的CHD trio 进行30X基因组测序(GS)。

主要发现

  • trio GS为4/13(30.8%)复杂CHD合并其他结构异常的胎儿提供了诊断。
  • 检出DNAH5、COL4A1、PTPN11和KRAS的致病或可能致病变异。
  • GS未明确遗传病因的9例中8例有结局随访,其中5例(60%)父母选择继续妊娠。
  • 一例携带双等位DNAH5突变的trio中检出平衡易位[46,XX,t(14;22)(q32.33;q13.31)mat],共同解释复发性胎儿内脏反位和右位心,后者推测由新发Phelan-McDermid综合征所致。
  • 队列中检出BRCA2变异次要发现及HBB、USH2A、HBA1/HBA2携带者状态。

临床怎么用

  • 作者提供证据支持将GS应用于CHD胎儿。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The diagnostic yield for congenital heart defects (CHD) with routine genetic testing is around 10%-20% when considering pathogenic CNVs or aneuploidies as positive findings. This is a pilot study to investigate the utility of genome sequencing (GS) for prenatal diagnosis of CHD. METHODS: Genome sequencing (GS, 30X) was performed on 13 trios with CHD for which karyotyping and/or chromosomal microarray results were non-diagnostic. RESULTS: Trio GS provided a diagnosis for 4/13 (30.8%) fetuses with complex CHDs and other structural anomalies. Findings included pathogenic or likely pathogenic variants in DNAH5, COL4A1, PTPN11, and KRAS. Of the nine cases without a genetic etiology by GS, we had outcome follow-up data on eight. For five of them (60%), the parents chose to keep the pregnancy. A balanced translocation [46,XX,t(14; 22)(q32.33; q13.31)mat] was detected in a trio with biallelic DNAH5 mutations, which together explained the recurrent fetal situs inversus and dextrocardia that was presumably due to de novo Phelan-McDermid syndrome. A secondary finding of a BRCA2 variant and carrier status of HBB, USH2A, HBA1/HBA2 were detected in the cohort. CONCLUSIONS: GS expands the diagnostic scope of mutation types over conventional testing, revealing the genetic etiology for fetal heart anomalies. Patients without a known genetic abnormality indicated by GS likely opted to keep pregnancy especially if the heart defect could be surgically repaired. We provide evidence to support the application of GS for fetuses with CHD.

来源:Prenat Diagn,查看原文。版权归原作者所有。

引用

  1. Cao Y, Chau MHK, Zheng Y, et al. Exploring the diagnostic utility of genome sequencing for fetal congenital heart defects. Prenat Diagn. 2022. PMID: 35441720. doi:10.1002/pd.6151

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。